High-risk HPV platforms and test of cure: Should specific HPV platforms more suited to screening in a 'test of cure' scenario be recommended?

Cytopathology

Volumn 26, Issue 6, 2015, Pages 381-387

  Innamaa, A ^a   Dudding, N ^b   Ellis, K ^b   Crossley, J ^b   Smith, J H ^c   Tidy, J A ^a   Palmer, J E ^a  

^a JESSOP HOSPITAL FOR WOMEN   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

Cervical intraepithelial neoplasia; Cobas 4800; High risk human papillomavirus; Hybrid Capture 2; Large loop excision of the transformation zone; Test of cure

Indexed keywords

ADULT; AGED; ARTICLE; COLPOSCOPY; CYTOLOGY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR KIT; ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; ELECTROSURGERY; ENGLAND; FALSE NEGATIVE RESULT; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURGERY; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; YOUNG ADULT;

VIRUS DNA;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; ELECTROSURGERY; ENGLAND; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84955566778     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12223     Document Type: Article

References (22)

1. Moss SM, Gray A, Legood R, Henstock E. Evaluation of HPV/LBC cervical screening pilot studies First report to the Department of Health on evaluation of LBC. (December 2002). Available at URL http://www.cancerscreening.nhs.uk/cervical/lbc-pilot-evaluation.pdf. Accessed November 2013.
2. Philips Z, Avis M, Whynes DK. Introducing HPV triage into the English cervical cancer screening program: consequences for participation. Women Health 2006;43:17-34.
3. Whynes DK, Woolley C, Philips Z. Trial of management of borderline and other low-grade abnormal smears group. Management of low-grade cervical abnormalities detected at screening: which method do women prefer? Cytopathology 2008;19:355-62.
4. Moss S, Kelly R, Legood R et al. Evaluation of Sentinel Sites for HPV triage and test of cure. Report to the NHS Cancer Screening Programmes. September 2011. Available at URL http://www.cancerscreening.nhs.uk/cervical/sentinelfinalreport.pdf. Accessed November 2013.
5. Digene HC2 High-Risk HPV DNA Test. Qiagen. Available at URL http://www.qiagen.com/products/catalog/assay-technologies/complete-assay-kits/hpv-testing/digene-hc2-high-risk-hpv-dna-test-ce. Accessed November 2013.
6. Cobas® 4800 System. Roche molecular diagnostics. Available at URL http://molecular.roche.com/instruments/Pages/cobas4800System.aspx. Accessed November 2013.
7. Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
8. de Sanjose S, Diaz M, Castellsague X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
9. Stoler MH, Wright TC Jr, Sharma A et al. ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011Mar;135:468-75.
10. Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
11. van den Snijders PJ, Brule AJ, Meijer CJ. The clinical relevance of human papilloma virus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
12. Wright TC Jr, Stoler MH, Sharma A et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136:578-86.
13. Lindemann ML, Dominguez MJ, de Antonio JC et al. Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of High-Risk HPV genotypes. J Mol Diagn 2012;14:65-70.
14. Lapierre SG, Sauthier P, Mayrand MH et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol 2012;50:1240-4.
15. Wright TC Jr, Stoler MH, Behrens CM et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-11.
16. Heideman DA, Hesselink AT, Berkhof J et al. Clinical validation of the cobas4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49:3983-5.
17. Lloveras B, Gomez S, Alameda F et al. HPV Testing by cobas HPV test in a population from Catalonia. PLoS ONE 2013;8:e58153.
18. Szarewski A, Mesher D, Cadman L et al. A comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867-73.
19. Preisler S, Rebolj M, Untermann A et al. Prevalence of human papillomavirus in 5, 072 consecutive cervical SurePath samples evaluated with the Roche Cobas HPV real-time PCR assay. PLoS ONE 2013;8:e59765.
20. Sargent A, Bailey A, Turner A et al. Optimal threshold for a positive Hybrid Capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010;48:554-8.
21. Cubie HA, Canham M, Moore C et al. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J Clin Pathol 2014; 2014 Jun;67(6):458-63.
22. NHSCSP. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme. NHSCSP publication number 20. Sheffield, UK: NHS Cancer Screening Programmes; 2010.